CN113728099A - Crispr/cas融合蛋白和系统 - Google Patents
Crispr/cas融合蛋白和系统 Download PDFInfo
- Publication number
- CN113728099A CN113728099A CN202080029346.8A CN202080029346A CN113728099A CN 113728099 A CN113728099 A CN 113728099A CN 202080029346 A CN202080029346 A CN 202080029346A CN 113728099 A CN113728099 A CN 113728099A
- Authority
- CN
- China
- Prior art keywords
- protein
- cells
- sequence
- fusion protein
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806708P | 2019-02-15 | 2019-02-15 | |
| US62/806708 | 2019-02-15 | ||
| PCT/US2020/018145 WO2020168102A1 (en) | 2019-02-15 | 2020-02-13 | Crispr/cas fusion proteins and systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113728099A true CN113728099A (zh) | 2021-11-30 |
Family
ID=70166116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080029346.8A Pending CN113728099A (zh) | 2019-02-15 | 2020-02-13 | Crispr/cas融合蛋白和系统 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10947517B2 (enExample) |
| EP (1) | EP3924475A1 (enExample) |
| JP (2) | JP2022520104A (enExample) |
| KR (1) | KR20210139271A (enExample) |
| CN (1) | CN113728099A (enExample) |
| AU (2) | AU2020221274B2 (enExample) |
| BR (1) | BR112021016019A2 (enExample) |
| CA (1) | CA3129835A1 (enExample) |
| IL (1) | IL285300A (enExample) |
| SG (1) | SG11202108812SA (enExample) |
| WO (1) | WO2020168102A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116063546A (zh) * | 2021-10-29 | 2023-05-05 | 深圳先进技术研究院 | 一种基于共振能量转移的全遗传编码nad+蛋白探针及其制备方法和应用 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| CA3129835A1 (en) | 2019-02-15 | 2020-08-20 | Sigma-Aldrich Co. Llc | Crispr/cas fusion proteins and systems |
| JP2024533311A (ja) * | 2021-09-08 | 2024-09-12 | フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー | ゲノムを調節するための方法及び組成物 |
| US20230265405A1 (en) * | 2022-02-22 | 2023-08-24 | Massachusetts Institute Of Technology | Engineered nucleases and methods of use thereof |
| WO2025221793A1 (en) * | 2024-04-16 | 2025-10-23 | Monsanto Technology Llc | Modified cas proteins for nuclear localization and editing activity in plants |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014186686A2 (en) * | 2013-05-17 | 2014-11-20 | Two Blades Foundation | Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases |
| US20160136293A1 (en) * | 2013-06-11 | 2016-05-19 | Portage Pharmaceuticals Ltd. | Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides |
| US20160355797A1 (en) * | 2013-12-12 | 2016-12-08 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
| WO2018071868A1 (en) * | 2016-10-14 | 2018-04-19 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
| CN107949400A (zh) * | 2015-06-24 | 2018-04-20 | 西格马-奥尔德里奇有限责任公司 | 细胞周期依赖性基因组调控和修饰 |
| CN108913676A (zh) * | 2012-12-06 | 2018-11-30 | 西格马-奥尔德里奇有限责任公司 | 基于crispr的基因组修饰和调控 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2468292A1 (en) | 2001-11-26 | 2003-06-05 | Advanced Cell Technology, Inc. | Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
| SI3401400T1 (sl) | 2012-05-25 | 2019-10-30 | Univ California | Postopki in sestavki za RNA usmerjeno modifikacijo tarčne DNA in za RNA usmerjeno modulacijo prepisovanja |
| EP3107562B1 (en) * | 2014-02-19 | 2019-09-18 | Bioasis Technologies Inc. | P97-ids fusion proteins |
| WO2015148863A2 (en) | 2014-03-26 | 2015-10-01 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
| KR102630014B1 (ko) | 2014-10-01 | 2024-01-25 | 더 제너럴 하스피탈 코포레이션 | 뉴클레아제-유도 상동성-지정 복구의 효율 증가 방법 |
| JP6867689B2 (ja) * | 2016-01-29 | 2021-05-12 | 国立大学法人東京工業大学 | Cas9−gRNA複合体の細胞核内への導入方法、及び細胞内における標的遺伝子の改変方法 |
| WO2017173004A1 (en) * | 2016-03-30 | 2017-10-05 | Mikuni Takayasu | A method for in vivo precise genome editing |
| EP4047092B1 (en) | 2016-04-13 | 2025-07-30 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
| CN107579793A (zh) * | 2016-07-04 | 2018-01-12 | 中兴通讯股份有限公司 | 一种通信网络设备间时间同步的优化方法、装置及设备 |
| KR20250103795A (ko) * | 2016-08-03 | 2025-07-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| US11242513B2 (en) | 2016-12-14 | 2022-02-08 | Wageningen Universiteit | Thermostable Cas9 nucleases |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
| EP4445954A3 (en) | 2017-07-31 | 2025-01-08 | Reflection Biotechnologies Limited | Cellular models of and therapies for ocular diseases |
| US11071791B2 (en) * | 2018-01-26 | 2021-07-27 | Wisconsin Alumni Research Foundation | Vector for gene silencing and replacement and methods of use thereof |
| KR102465067B1 (ko) | 2018-02-15 | 2022-11-10 | 시그마-알드리치 컴퍼니., 엘엘씨 | 진핵 게놈 변형을 위한 조작된 cas9 시스템 |
| CN112041444A (zh) * | 2018-03-14 | 2020-12-04 | 阿伯生物技术公司 | 新型crispr dna靶向酶及系统 |
| CA3129835A1 (en) | 2019-02-15 | 2020-08-20 | Sigma-Aldrich Co. Llc | Crispr/cas fusion proteins and systems |
-
2020
- 2020-02-13 CA CA3129835A patent/CA3129835A1/en active Pending
- 2020-02-13 CN CN202080029346.8A patent/CN113728099A/zh active Pending
- 2020-02-13 SG SG11202108812SA patent/SG11202108812SA/en unknown
- 2020-02-13 WO PCT/US2020/018145 patent/WO2020168102A1/en not_active Ceased
- 2020-02-13 EP EP20716979.8A patent/EP3924475A1/en active Pending
- 2020-02-13 BR BR112021016019-1A patent/BR112021016019A2/pt unknown
- 2020-02-13 KR KR1020217029732A patent/KR20210139271A/ko not_active Ceased
- 2020-02-13 US US16/790,399 patent/US10947517B2/en active Active
- 2020-02-13 AU AU2020221274A patent/AU2020221274B2/en not_active Ceased
- 2020-02-13 JP JP2021547390A patent/JP2022520104A/ja active Pending
-
2021
- 2021-02-10 US US17/172,734 patent/US11965184B2/en active Active
- 2021-08-02 IL IL285300A patent/IL285300A/en unknown
-
2023
- 2023-04-27 US US18/308,336 patent/US20230287377A1/en not_active Abandoned
- 2023-07-27 JP JP2023122299A patent/JP2023156365A/ja active Pending
-
2024
- 2024-04-09 AU AU2024202275A patent/AU2024202275A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108913676A (zh) * | 2012-12-06 | 2018-11-30 | 西格马-奥尔德里奇有限责任公司 | 基于crispr的基因组修饰和调控 |
| WO2014186686A2 (en) * | 2013-05-17 | 2014-11-20 | Two Blades Foundation | Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases |
| US20160136293A1 (en) * | 2013-06-11 | 2016-05-19 | Portage Pharmaceuticals Ltd. | Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides |
| US20160355797A1 (en) * | 2013-12-12 | 2016-12-08 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
| CN107949400A (zh) * | 2015-06-24 | 2018-04-20 | 西格马-奥尔德里奇有限责任公司 | 细胞周期依赖性基因组调控和修饰 |
| WO2018071868A1 (en) * | 2016-10-14 | 2018-04-19 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
Non-Patent Citations (2)
| Title |
|---|
| PEI ZHAO ET AL: "One-step homozygosity in precise gene editing by an improved CRISPR/Cas9 system", 《CELL RESEARCH》, 8 April 2016 (2016-04-08), pages 633 * |
| 姚文兵 等: "《生物技术制药概论》", 31 August 2015, 中国医药科技出版社, pages: 75 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116063546A (zh) * | 2021-10-29 | 2023-05-05 | 深圳先进技术研究院 | 一种基于共振能量转移的全遗传编码nad+蛋白探针及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL285300A (en) | 2021-09-30 |
| US20230287377A1 (en) | 2023-09-14 |
| SG11202108812SA (en) | 2021-09-29 |
| AU2020221274A1 (en) | 2021-08-26 |
| AU2024202275A1 (en) | 2024-05-23 |
| US20200263155A1 (en) | 2020-08-20 |
| US11965184B2 (en) | 2024-04-23 |
| AU2020221274B2 (en) | 2024-02-08 |
| US10947517B2 (en) | 2021-03-16 |
| KR20210139271A (ko) | 2021-11-22 |
| JP2022520104A (ja) | 2022-03-28 |
| JP2023156365A (ja) | 2023-10-24 |
| US20210163910A1 (en) | 2021-06-03 |
| EP3924475A1 (en) | 2021-12-22 |
| CA3129835A1 (en) | 2020-08-20 |
| BR112021016019A2 (pt) | 2021-10-05 |
| WO2020168102A1 (en) | 2020-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021200636B2 (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
| JP7469285B2 (ja) | 標的化されたゲノム修飾を増強するためのヌクレオソーム相互作用タンパク質ドメインの使用 | |
| JP7559005B2 (ja) | 真核ゲノム修飾のための操作されたCas9システム | |
| US20230287377A1 (en) | Crispr/cas fusion proteins and systems | |
| JP2020530992A (ja) | Crispr/casアクチベーターシステムのための合成ガイドrna | |
| JP7629673B2 (ja) | ゲノム改変のための高忠実度SpCas9ヌクレアーゼ | |
| HK40075530A (en) | High fidelity spcas9 nucleases for genome modification | |
| HK40040051A (en) | Engineered cas9 systems for eukaryotic genome modification | |
| HK40023852A (en) | Synthetic guide rna for crispr/cas activator systems | |
| HK40040051B (zh) | 用於真核基因组修饰的改造的cas9系统 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211130 |
|
| WD01 | Invention patent application deemed withdrawn after publication |